FTC approves AbbVie’s proposed $63 billion deal to buy Allergan

On the other hand, FTC’s Republican majority fired back at Chopra. According to them, “His dissent makes misleading claims about the staff’s investigation, the state of competition in the pharmaceutical industry, and the Commission’s enforcement record in this industry. It relies on false assertions, misapplication of [the] law, and specious logic. It appears to have fully embraced the adage to “never let the truth get in the way of a good story” and engages in unbounded speculation while criticizing forecasts based on rigorous investigation and grounded in evidence. Where facts conflict with theory, we follow the facts, even if they lead to an outcome we do not like.”